Shijiazhuang Yiling Pharmaceutical Co,Ltd.
Home - News

[News]Shijiazhuang Yiling Pharmaceutical

[News]Shijiazhuang Yiling Pharmaceutical
National key high-tech enterprises——Shijiazhuang Yiling Pharmaceutical Co., Ltd. (stock code 002603) was created by Academician Wu Yiling, Chinese Academy of Engineering
Yiling Pharmaceutical
Jian, under his leadership, Yiling Pharmaceutical has always adhered to the science and technology as the forerunner and market-led scientific and technological innovation development strategy, and created a unique operation mode of “theory-clinical-scientific research-industry-teaching”. Innovative technology system for new drug research and development guided by theoretical innovation of TCM collateral disease. The leaders of the Ministry of Science and Technology have praised the development model of the Five-in-One as "the pioneering work of the scientific and technological achievements of Chinese medicine."
In the development process of Yiling Pharmaceutical, a large number of scientific research, production, management and marketing teams have been gathered, including returning experts, foreign experts, doctors, masters and various high-level talents. It is the Hebei Biomedical Academician workstation and national personnel. Postdoctoral research station, doctoral and master's degree training base of Hebei Medical University.
Yiling Pharmaceutical promotes the industrialization of traditional Chinese medicine with the theory of collateral disease, and uses modern high-tech to develop traditional Chinese medicine, western medicine and biological medicine, and research and develop more than 10 national patent new drugs covering cardiovascular and cerebrovascular diseases, cold respiratory diseases, tumors and diabetes. And other major disease areas. Yiling Pharmaceutical has a Chinese medicine production line that has passed the national GMP certification [4] and a chemical production workshop that has passed the EU certification [5]. Yiling Pharmaceutical is a national innovative enterprise [6] and a top 20 listed company in China.
The main business of Ling Pharmaceutical Industry is the R&D, production and sales of traditional Chinese medicine. In the field of diseases, the company ranks first in the field of medication for cardiovascular, cerebrovascular and respiratory diseases. Among its products, Lianhua Qingwen Capsules/Granules for treating colds and influenza entered the National Essential Medicines Catalogue (2018 edition), which is the basic medicine for treating colds.Yiling Pharmaceuticals provide jujube seed oil,you can know it.
On November 20, 2018, the General Office of the State Health Commission and the Office of the State Administration of Traditional Chinese Medicine jointly issued the Influenza Diagnosis and Treatment Program (Revised Version 2018). Lianhua Qingwen Capsule/Granule was once again listed as recommended medication. At the same time, Jinhua Qinggan Granule, Qingkailing Granule (Capsule, Soft Capsule, Tablet), Shufeng Jiedu Capsule, Yinqiao Jiedu Capsule, Sangju were also recommended.
All along, cold is a common and multiple disease, and cold medicine is almost a household drug. Because of its high incidence and wide susceptibility, the market demand for cold medicine has been rising. According to Zhongkang CMH data, cold medicine is the largest category in the retail market.
According to incomplete statistics, 75% of the people in China suffer from a cold at least once a year, that is to say, nearly 1 billion people need to use cold medicine at least once a year. Data show that the average cost of cold medication is 25 yuan per time.
The compound growth rate of cold medicines is 15% between 2012 and 2016, and the market scale will reach 95 billion yuan by 2022.
The market of Zhongcheng cold medicine has been fiercely competitive. According to the data of MineNet, the sales revenue of Chinese patent medicines for cold medicines in TOP10 in 2017 was 6.54%, 6.24%, 4.74%, 4.21% and 3.75% of the market share of Shufeng Jiedu Capsule, Lianhua Qingwen Granule, Zukamu Granule, Lianhua Qingwen Capsule and Shuanghuanglian Granule of Harbin Children's Pharmaceutical in Anhui Jiren Pharmaceutical Industry.
According to the data of Zhongkang Information, in the TOP10 of OTC terminal cold medicines in 2018, the top five were Huarun 399 (000999.SZ) Ganmaoling granules, Pudilan Xiaoyan oral liquid of Jichuan Pharmaceutical Industry (600566.SH), Huoxiang Zhengqi oral liquid of Taiji Group (600129.SH), Huarun 399 Compound Ganmaoling granules and Lianhuaqing of Yiling Pharmaceutical Industry. Pestilence Capsules, Andrographolide Dropping Pills of Tianshili (600535. SH) and Pudilan Anti-inflammatory Tablets of Yunnan Baiyao (000538. SZ) also ranked in the top 10.
Shijiazhuang Yiling Pharmaceutical was awarded the “Most Cooperative Industrial Brand Enterprise of Chinese Chain Drugstores”
On July 15th, 2018 China's top 100 pharmaceutical industry list was held in Jinan. As the highlight of the 2019 National Pharmacy Week, “2019 China Chain Drugstore's Most Cooperative Industrial Brand Enterprise” was unveiled in Jinan Shandong Building! Yiling Pharmaceuticals praised “2019 China Chain Pharmacy Most Cooperative Industrial Brand Enterprise”.
This is the second industry honor that Lingling Pharmaceuticals has won after the “Top 100 Chinese Pharmaceutical Industry” in the 2019 pharmacy week.
The 2019 National Pharmacy Week and China Pharmaceutical Innovation and Development Summit, the theme of “Reconstruction of Value – Searching for Growth, Expanding Boundaries, and Exploring the Future”, under the current situation of rapid changes in policy and market environment and accelerated restructuring of the pharmaceutical retail industry, Look for new growth points in the hot policy of the pharmaceutical industry, develop and break through the development boundary in the new competitive environment, and seize the commanding heights of the future.

In the past 27 years, Yiling Pharmaceutical has always adhered to the market leading and technology-driven innovation development strategy, and created a unique operation mode of “theory-clinical-scientific research-industry-teaching”.

Shijiazhuang Yiling Pharmaceutical

Next: No more!!